{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T14:28:00Z","timestamp":1788964080295,"version":"build-2803163510"},"reference-count":42,"publisher":"Georg Thieme Verlag KG","issue":"01","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmacopsychiatry"],"published-print":{"date-parts":[[2022,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>\nIntroduction The SARS-CoV-2 pandemic with psychiatric comorbidities leads to a scenario in which the use of psychotropic drugs may be required. This requires the support of evidence-based medicine to take into account possible interactions between antidepressants, mood stabilizers, benzodiazepines, and coronavirus infection treatments.<\/jats:p><jats:p>\nMethods Three databases were consulted: (a) Lexicomp Drug Interactions, (b) Micromedex Solutions Drugs Interactions, (c)Liverpool Drug Interaction Group for COVID-19 therapies. The CredibleMeds QTDrugs List was also queried. Hydroxychloroquine, chloroquine, azithromycin, lopinavir-ritonavir, remdesivir, favipiravir, tocilizumab, baricitinib, anakinra, and dexamethasone \u2013 drugs used for SARS-CoV-2 \u2013 were analyzed, and consensus recommendations are made.<\/jats:p><jats:p>\nResults The potential interactions of agomelatine, desvenlafaxine, duloxetine, milnacipran, and vortioxetine with COVID-19 treatments shall be considered less risky. Antidepressant interactions with hydroxychloroquine, chloroquine, and azithromycin enhance the risk of QT prolongation, and ECG monitoring is advised for most antidepressants. Antidepressants with lopinavir\/ritonavir involve multiple CYP enzyme interactions (except with milnacipran). Gabapentin, oxcarbazepine, pregabalin, topiramate, and zonisamide are safe treatment options that have no significant interactions with COVID-19 treatments. Lithium is contraindicated with hydroxychloroquine, chloroquine, and azithromycin. Precaution should be taken in using valproic acid with lopinavir-ritonavir. The use of benzodiazepines does not present a risk of drug interaction with COVID-19 treatments, except lopinavir\/ritonavir.<\/jats:p><jats:p>\nConclusions Clinicians prescribing antidepressants, mood stabilizers\/anticonvulsants, and benzodiazepines, should be aware of the probable risk of drug-drug interaction with COVID-19 medications and may benefit from heeding these recommendations for use to ensure patient safety.<\/jats:p>","DOI":"10.1055\/a-1492-3293","type":"journal-article","created":{"date-parts":[[2021,6,25]],"date-time":"2021-06-25T22:38:20Z","timestamp":1624660700000},"page":"40-47","source":"Crossref","is-referenced-by-count":16,"title":["Drug-drug Interactions between COVID-19 Treatments and Antidepressants, Mood Stabilizers\/Anticonvulsants, and Benzodiazepines: Integrated Evidence from 3 Databases"],"prefix":"10.1055","volume":"55","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1141-0833","authenticated-orcid":false,"given":"Beatriz Oda","family":"Plasencia-Garc\u00eda","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, University Hospital Virgen del Rocio Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Isabel","family":"Rico-Rangel","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, University Hospital Virgen del Rocio Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gonzalo","family":"Rodr\u00edguez-Men\u00e9ndez","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, University Hospital Virgen del Rocio Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Rubio-Garc\u00eda","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, University Hospital Virgen del Rocio Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaime","family":"Torell\u00f3-Iserte","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology, University Hospital Virgen del Rocio Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedicto","family":"Crespo-Facorro","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, University Hospital Virgen del Rocio Spain"},{"name":"Biomedical Research Centre in Mental Health Network (CIBERSAM) Spain"},{"name":"University of Sevilla Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2021,6,25]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.rpsm.2020.04.010","article-title":"Mental health and the SARS-CoV-2 pandemic","volume":"13","author":"B Crespo-Facorro","year":"2020","journal-title":"Rev Psiquiatr Salud Ment"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1331\/154434504773062582","article-title":"Concordance of severity ratings provided in four drug interaction compendia","volume":"44","author":"J Abarca","year":"2004","journal-title":"J Am Pharm Assoc JAPhA"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"105","DOI":"10.2165\/00128071-200506020-00005","article-title":"Lack of drug interaction conformity in commonly used drug compendia for selected at-risk dermatologic drugs","volume":"6","author":"S D Chao","year":"2005","journal-title":"Am J Clin Dermatol"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/S0011-393X(00)80036-3","article-title":"Disagreement among drug compendia on inclusion and ratings of drug-drug interactions","volume":"8","author":"T R Fulda","year":"2000","journal-title":"Curr Ther Res"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1111\/j.1365-2125.2006.02809.x","article-title":"Comparative assessment of four drug interaction compendia","volume":"63","author":"AI Vitry","year":"2007","journal-title":"Br J Clin Pharmacol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1016\/j.psychres.2019.03.041","article-title":"A comparison of potential psychiatric drug interactions from six drug interaction database programs","volume":"275","author":"S Monteith","year":"2019","journal-title":"Psychiatry Res"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1055\/a-1156-4193","article-title":"Potential drug interactions with drugs used for bipolar disorder: A comparison of 6 drug interaction database programs","volume":"53","author":"S Monteith","year":"2020","journal-title":"Pharmacopsychiatry"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2020.09.079","article-title":"Short-term emotional impact of COVID-19 pandemic on Spaniard health workers","author":"G Rodriguez-Menendez","year":"2020","journal-title":"J Affect Disord"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph17051729","article-title":"Immediate psychological responses and associated factors during the initial stage of the 2019 coronavirus disease (COVID-19) epidemic among the general population in China","volume":"17","author":"C Wang","year":"2020","journal-title":"Int J Environ Res Public Health"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1037\/tra0000924","article-title":"Fear of COVID-19 and the mental health consequences in America","author":"K M Fitzpatrick","year":"2020","journal-title":"Psychol Trauma Theory Res Pract Policy"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbi.2020.05.048","article-title":"COVID-19 pandemic and mental health consequences: Systematic review of the current evidence","author":"N Vindegaard","year":"2020","journal-title":"Brain Behav Immun"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"e2019686","DOI":"10.1001\/jamanetworkopen.2020.19686","article-title":"Prevalence of depression symptoms in US adults before and during the COVID-19 pandemic","volume":"3","author":"C K Ettman","year":"2020","journal-title":"JAMA Netw Open"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"113130.","DOI":"10.1016\/j.psychres.2020.113130","article-title":"Depression, anxiety, stress levels of physicians and associated factors in Covid-19 pandemics","volume":"290","author":"R Y Elbay","year":"2020","journal-title":"Psychiatry Res"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"m1642","DOI":"10.1136\/bmj.m1642","article-title":"Occurrence, prevention, and management of the psychological effects of emerging virus outbreaks on healthcare workers: rapid review and meta-analysis","volume":"369","author":"S Kisely","year":"2020","journal-title":"BMJ"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1192\/bjp.2020.92","article-title":"Safe and informed prescribing of psychotropic medication during the COVID-19 pandemic","author":"J J Luykx","year":"2020","journal-title":"Br J Psychiatry"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.6019","article-title":"Pharmacologic treatments for coronavirus disease 2019 (COVID-19): A review","author":"J M Sanders","journal-title":"JAMA 2020"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"105949.","DOI":"10.1016\/j.ijantimicag.2020.105949","article-title":"Hydroxychloroquine and azithromycin as a treatment of COVID-19: Results of an open-label non-randomized clinical trial","author":"P Gautret","year":"2020","journal-title":"Int J Antimicrob Agents"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmii.2020.03.034","article-title":"Treatment options for COVID-19: the reality and challenges","author":"S-S Jean","year":"2020","journal-title":"J Microbiol Immunol Infect Wei Mian Yu Gan Ran Za Zhi"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2020.04.017","article-title":"Baricitinib therapy in COVID-19: a pilot study on safety and clinical impact","author":"F Cantini","year":"2020","journal-title":"J Infect"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1002\/acr2.11135","article-title":"Continuous Intravenous anakinra infusion to calm the cytokine storm in macrophage activation syndrome","author":"L A Monteagudo","year":"2020","journal-title":"ACR Open Rheumatol"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/S1130-6343(09)71155-9","article-title":"Calidad estructural de las bases de datos de interacciones","volume":"33","author":"A Rodr\u00edguez-Terol","year":"2009","journal-title":"Farm Hosp"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"290","DOI":"10.3163\/1536-5050.104.4.007","article-title":"Evaluation of resources for analyzing drug interactions","volume":"104","author":"R I Patel","year":"2016","journal-title":"J Med Libr Assoc JMLA"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2001282","article-title":"A Trial of lopinavir-ritonavir in adults hospitalized with severe covid-19","author":"B Cao","year":"2020","journal-title":"N Engl J Med"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1345\/aph.1K615","article-title":"Induction effects of ritonavir: implications for drug interactions","volume":"42","author":"M M Foisy","year":"2008","journal-title":"Ann Pharmacother"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.4088\/PCC.20com02677","article-title":"Ritonavir\/Lopinavir and its potential interactions with psychiatric medications: a COVID-19 perspective","volume":"22","author":"Z Mansuri","year":"2020","journal-title":"Prim Care Companion CNS Disord"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"20958.","DOI":"10.1038\/s41598-020-78029-3","article-title":"High rate of major drug-drug interactions of lopinavir-ritonavir for COVID-19 treatment","volume":"10","author":"J Mac\u00edas","year":"2020","journal-title":"Sci Rep"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1007\/s40266-020-00812-8","article-title":"Drug-Drug interactions and prescription appropriateness in patients with COVID-19: a retrospective analysis from a reference hospital in northern Italy","volume":"37","author":"D Cattaneo","year":"2020","journal-title":"Drugs Aging"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.medcli.2020.06.026","article-title":"Potential drug-drug interactions in COVID 19 patients in treatment with lopinavir\/ritonavir","volume":"155","author":"D Brandariz-Nu\u00f1ez","year":"2020","journal-title":"Med Clin (Barc)"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1007\/s11739-020-02586-8","article-title":"Adverse drug reactions in SARS-CoV-2 hospitalised patients: a case-series with a focus on drug-drug interactions","author":"G Crescioli","year":"2020","journal-title":"Intern Emerg Med"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1111\/jcpt.13337","article-title":"Real-world prevalence and consequences of potential drug-drug interactions in the first-wave COVID-19 treatments","author":"N Mart\u00ednez-L\u00f3pez-de-Castro","year":"2020","journal-title":"J Clin Pharm Ther"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"e013433.","DOI":"10.1136\/bmjopen-2016-013433","article-title":"Biological rationale and potential clinical use of gabapentin and pregabalin in bipolar disorder, insomnia and anxiety: protocol for a systematic review and meta-analysis","volume":"7","author":"K T Houghton","year":"2017","journal-title":"BMJ Open"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"228.","DOI":"10.3389\/fpsyt.2019.00228","article-title":"Use of gabapentin in the treatment of substance use and psychiatric disorders: a systematic review","volume":"10","author":"S Ahmed","year":"2019","journal-title":"Front Psychiatry"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1016\/S0140-6736(18)31793-8","article-title":"Pharmacological treatments for generalised anxiety disorder: a systematic review and network meta-analysis","volume":"393","author":"A Slee","year":"2019","journal-title":"Lancet Lond Engl"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1177\/0269881115598411","article-title":"Efficacy and safety of pregabalin in generalised anxiety disorder: a critical review of the literature","volume":"29","author":"D S Baldwin","year":"2015","journal-title":"J Psychopharmacol Oxf Engl"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1097\/SPC.0000000000000395","article-title":"Benzodiazepines for agitation in patients with delirium: selecting the right patient, right time, and right indication. Curr Opin Support","volume":"12","author":"D Hui","year":"2018","journal-title":"Palliat Care"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"508","DOI":"10.3238\/arztebl.2019.0508","article-title":"Psychopharmacological treatment in older people","volume":"116","author":"T Kratz","year":"2019","journal-title":"Dtsch \u00c4rztebl Int"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/S2213-2600(20)30552-X","article-title":"Prevalence and risk factors for delirium in critically ill patients with COVID-19 (COVID-D): a multicentre cohort study. Lancet","volume":"9","author":"B T Pun","year":"2021","journal-title":"Respir Med"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/s1470-2045(03)01034-9","article-title":"Inflammatory response: an unrecognised source of variability in the pharmacokinetics and pharmacodynamics of cancer chemotherapy","volume":"4","author":"K A Slaviero","year":"2003","journal-title":"Lancet Oncol"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1586\/ecp.11.66","article-title":"Inflammation-mediated changes in drug transporter expression\/activity: implications for therapeutic drug response","volume":"5","author":"A M Cressman","year":"2012","journal-title":"Expert Rev Clin Pharmacol"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1124\/mi.7.2.10","article-title":"Regulation of drug transporters during infection and inflammation","volume":"7","author":"V Petrovic","year":"2007","journal-title":"Mol Interv"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1146\/annurev.pharmtox.46.120604.141059","article-title":"Regulation of drug-metabolizing enzymes and transporters in inflammation","volume":"46","author":"A E Aitken","year":"2006","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1080\/17425255.2017.1311323","article-title":"Inflammation and pharmacokinetics: potential implications for HIV-infection","volume":"13","author":"S M Seifert","year":"2017","journal-title":"Expert Opin Drug Metab Toxicol"}],"container-title":["Pharmacopsychiatry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-1492-3293.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,28]],"date-time":"2022-01-28T02:41:20Z","timestamp":1643337680000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-1492-3293"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,25]]},"references-count":42,"journal-issue":{"issue":"01","published-online":{"date-parts":[[2022,1,25]]},"published-print":{"date-parts":[[2022,1]]}},"URL":"https:\/\/doi.org\/10.1055\/a-1492-3293","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0176-3679","1439-0795"],"issn-type":[{"value":"0176-3679","type":"print"},{"value":"1439-0795","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,25]]}}}